APYX vs. OBIO, PROF, SKIN, BWAY, KRMD, NVRO, INFU, LAKE, TLSI, and SGHT
Should you be buying Apyx Medical stock or one of its competitors? The main competitors of Apyx Medical include Orchestra BioMed (OBIO), Profound Medical (PROF), Beauty Health (SKIN), BrainsWay (BWAY), KORU Medical Systems (KRMD), Nevro (NVRO), InfuSystem (INFU), Lakeland Industries (LAKE), TriSalus Life Sciences (TLSI), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.
Apyx Medical vs.
Orchestra BioMed (NASDAQ:OBIO) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
In the previous week, Apyx Medical had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 2 mentions for Apyx Medical and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.89 beat Apyx Medical's score of 0.85 indicating that Orchestra BioMed is being referred to more favorably in the media.
Orchestra BioMed currently has a consensus target price of $16.25, suggesting a potential upside of 186.85%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts plainly believe Orchestra BioMed is more favorable than Apyx Medical.
Orchestra BioMed has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Apyx Medical has a net margin of -58.59% compared to Orchestra BioMed's net margin of -2,179.33%. Orchestra BioMed's return on equity of -107.04% beat Apyx Medical's return on equity.
53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 55.3% of Apyx Medical shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by insiders. Comparatively, 16.8% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Apyx Medical has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.
Apyx Medical received 66 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 60.94% of users gave Apyx Medical an outperform vote.
Summary
Apyx Medical beats Orchestra BioMed on 12 of the 19 factors compared between the two stocks.
Get Apyx Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for APYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apyx Medical Competitors List
Related Companies and Tools
This page (NASDAQ:APYX) was last updated on 1/31/2025 by MarketBeat.com Staff
